BidaskClub lowered shares of LivaNova (NASDAQ:LIVN) from a buy rating to a hold rating in a report published on Thursday.
Other analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of LivaNova from a hold rating to a buy rating and set a $89.00 target price on the stock in a report on Thursday, November 9th. BTIG Research restated a hold rating on shares of LivaNova in a report on Tuesday, November 7th. Piper Jaffray Companies restated a buy rating and issued a $85.00 target price on shares of LivaNova in a report on Friday, November 3rd. Canaccord Genuity restated a hold rating and issued a $71.00 target price on shares of LivaNova in a report on Wednesday, September 20th. Finally, ValuEngine downgraded shares of LivaNova from a buy rating to a hold rating in a report on Wednesday, December 20th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of Hold and an average price target of $79.71.
LivaNova (NASDAQ:LIVN) traded up $1.89 during trading on Thursday, hitting $83.81. 468,907 shares of the stock were exchanged, compared to its average volume of 375,594. LivaNova has a 12-month low of $45.67 and a 12-month high of $88.56. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.42 and a current ratio of 2.03. The company has a market cap of $3,950.00 and a P/E ratio of 22.35.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $82.15, for a total transaction of $82,150.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Hugh M. Morrison sold 1,830 shares of LivaNova stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $88.00, for a total transaction of $161,040.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,830 shares of company stock valued at $576,920. 0.28% of the stock is owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in shares of LivaNova by 79.3% during the 2nd quarter. BlackRock Inc. now owns 4,648,780 shares of the company’s stock worth $284,552,000 after purchasing an additional 2,055,891 shares during the period. State Street Corp boosted its position in LivaNova by 74.8% in the 2nd quarter. State Street Corp now owns 1,835,428 shares of the company’s stock valued at $112,345,000 after buying an additional 785,268 shares during the period. Koch Industries Inc. purchased a new stake in LivaNova in the 2nd quarter valued at about $1,384,000. Dimensional Fund Advisors LP boosted its position in LivaNova by 42.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,317,901 shares of the company’s stock valued at $92,331,000 after buying an additional 395,672 shares during the period. Finally, Vanguard Group Inc. boosted its position in LivaNova by 13.6% in the 2nd quarter. Vanguard Group Inc. now owns 883,058 shares of the company’s stock valued at $54,052,000 after buying an additional 105,702 shares during the period. 86.00% of the stock is owned by hedge funds and other institutional investors.
LivaNova Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.